Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies

Bone Marrow Transplantation volume 46, pages 1540–1544 (2011)Cite this article

Subjects

Abstract

Therapy-related myeloid neoplasms (t-MNs) are severe long-term consequences of cytotoxic treatments for a primary, often, malignant disorder. So far, the majority of patients eligible for transplantation have undergone myeloablative allo haematopoietic SCT (HSCT) as a potentially curative treatment, but it has been associated with high transplantation-related mortality (TRM) rates. In this retrospective study, we analysed the outcome of patients with t-MNs undergoing HSCT with reduced-intensity conditioning (RIC). Of 55 patients, seen at a single centre over a 10-year period, 17 underwent RIC HSCT with related or unrelated donors. The estimated overall survival was 53% at 1 year and 47% at 3 years, and disease-free survival was 47% at 1 year. At 1 year, the cumulative incidence of relapse and TRM were 24% and 30%, respectively. Of five patients with active primary neoplasms who underwent transplantation, two are alive beyond 1 year and show CR of both t-MNs and the primary malignancy. These data indicate that RIC HSCT is an encouraging approach for patients with t-MNs. The issue of primary malignancies not being in remission at the time of transplantation should be explored in further studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A . Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 2011; 162: 792–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104: 822–828.

    Article  CAS  PubMed  Google Scholar 

  3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  PubMed  Google Scholar 

  4. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002; 16: 2366–2378.

    Article  CAS  PubMed  Google Scholar 

  5. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.

    Article  CAS  PubMed  Google Scholar 

  6. Andersen MT, Andersen MK, Christiansen DH, Pedersen-Bjergaard J . NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008; 22: 951–955.

    Article  CAS  PubMed  Google Scholar 

  7. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C . Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22: 2510–2511.

    Article  PubMed  Google Scholar 

  8. Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137–2145.

    Article  CAS  PubMed  Google Scholar 

  9. Larson RA . Therapy-related myeloid neoplasms. Haematologica 2009; 94: 454–459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578–2585.

    CAS  PubMed  Google Scholar 

  11. Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR . Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134–2141.

    Article  CAS  PubMed  Google Scholar 

  12. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963–971.

    Article  CAS  PubMed  Google Scholar 

  13. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379–1387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Woodard P, Barfield R, Hale G, Horwitz E, Leung W, Ribeiro RC et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006; 47: 931–935.

    Article  PubMed  Google Scholar 

  15. Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ . Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol 2009; 31: 803–811.

    Article  PubMed  Google Scholar 

  16. Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542–549.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850–1857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Storb R . Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009; 21 (Suppl 1): 3–5.

    Article  Google Scholar 

  19. Nelson Jr RP, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 2010; 45: 1300–1308.

    Article  CAS  PubMed  Google Scholar 

  20. Khabori MA, El-Emary M, Xu W, Guyatt G, Galal A, Kuruvilla J et al. Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant 2011; 46: 516–522.

    Article  CAS  PubMed  Google Scholar 

  21. El Kourashy S, Williamson T, Chaudhry MA, Savoie ML, Turner AR et al. Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone Marrow Transplant 2010; (e-pub ahead of print 8 November 2010; doi: 10.1038/bmt.2010.257).

  22. Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336–342.

    Article  PubMed  Google Scholar 

  23. Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006; 37: 339–344.

    Article  PubMed  Google Scholar 

  24. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727–736.

    Article  PubMed  Google Scholar 

  25. Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M et al. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 84–89.

    Article  CAS  PubMed  Google Scholar 

  26. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  27. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  28. Kim HT . Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559–565.

    Article  PubMed  Google Scholar 

  29. Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V et al. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer 2008; 112: 1513–1521.

    Article  PubMed  Google Scholar 

  30. Perez-Simon JA, Martino R, Alegre A, Tomas JF, De Leon A, Caballero D et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108.

    Article  PubMed  Google Scholar 

  31. Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E . Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655–3663.

    Article  CAS  PubMed  Google Scholar 

  32. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.

    Article  CAS  PubMed  Google Scholar 

  33. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848.

    Article  CAS  PubMed  Google Scholar 

  34. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G et al. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant 2009; 44: 579–583.

    Article  CAS  PubMed  Google Scholar 

  35. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M . The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614–633.

    Article  PubMed  Google Scholar 

  36. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008; 5: 256–267.

    Article  CAS  PubMed  Google Scholar 

  37. Toh HC, Chia WK, Sun L, Thng CH, Soe Y, Phoon YP et al. Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. Bone Marrow Transplant 2011; 46: 573–579.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ms Eugenia Lamont for editing the manuscript. This work was supported by a grant from the Jubiläumsfonds, Austrian National Bank (Nr. 13918) and Leukämiehilfe Steiermark.

Author information

Authors and Affiliations

  1. Division of Haematology, Medical University of Graz, Graz, Austria

    W Zinke-Cerwenka, A Valentin, W Linkesch, A Wölfler & H Sill

  2. Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria

    U Posch

  3. Institute of Pathology, Medical University of Graz, Graz, Austria

    C Beham-Schmid

  4. Biostatistics, Centre for Medical Research,

    A Groselj-Strele

  5. , Medical University of Graz, Graz, Austria

    A Groselj-Strele

Authors
  1. W Zinke-Cerwenka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Valentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Posch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Beham-Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Groselj-Strele
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W Linkesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Wölfler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Sill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Sill.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zinke-Cerwenka, W., Valentin, A., Posch, U. et al. Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies. Bone Marrow Transplant 46, 1540–1544 (2011). https://doi.org/10.1038/bmt.2011.165

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.165

Keywords

This article is cited by

Search

Advanced search

Quick links